Vibegron equally effective in OAB wet and dry patients
April 26th 2022“In this subgroup analysis of data from the EMPOWUR trial, vibegron was associated with significant reductions in urgency episodes and micturitions compared with placebo in both the OAB dry and wet populations,” said lead author Jeffrey Frankel, MD.
Novel TKI/immunotherapy combo shows promise in advanced kidney cancer
April 22nd 2022Combination therapy with the novel TKI sitravatinib and the anti–PD-1 immune checkpoint inhibitor nivolumab showed promising efficacy and safety in patients with clear cell renal cell carcinoma and progression after antiangiogenic therapy.
Enfortumab Vedotin approved in EU for urothelial cancer
April 14th 2022The approval was based on data from the phase 3 EV-301 trial, in which enfortumab vedotin reduced the risk of death by 30% versus chemotherapy in patients with heavily pretreated locally advanced or metastatic urothelial carcinoma.
Study launches of Cu-64 SAR-bisPSMA in biochemically recurrent prostate cancer
April 1st 2022Eligible patients for the multicenter, nonrandomized, single-arm trial (NCT05249127) will have suspected recurrence of prostate cancer as determined by a rising prostate-specific antigen following definitive therapy.
FDA approves companion diagnostic for pembrolizumab in MSI-H solid tumors
February 22nd 2022The emergence of tumor-agnostic approvals, such as pembrolizumab for MSI-H solid tumors, has increased the significance of genomic profiling in urology, as patients with prostate, bladder, or kidney cancer may benefit from these therapies.
Neoadjuvant avelumab/axitinib shows promise in renal cell carcinoma
February 20th 2022The combination of the PD-L1 inhibitor avelumab and the tyrosine kinase inhibitor axitinib showed promise as a neoadjuvant therapy for patients with high-risk, non-metastatic clear-cell renal cell carcinoma, according to findings from the NeoAvAx trial.
Study demonstrates feasibility of antegrade instillation of Jelmyto for UTUC
February 11th 2022“While Jelmyto is approved for both retrograde and antegrade instillation, the instructions for administration address retrograde instillation, and this is the first time that data on antegrade instillation has been documented in a clinical setting for this chemoablative therapy,” said Katie Murray, DO.
PARP inhibitor niraparib shows promise in mCRPC with DNA repair gene defects
February 10th 2022“Such findings underscore the need for and importance of molecular testing to inform management along with continued research to establish treatment paradigms with appropriately targeted therapies for patients with prostate cancer,” the authors wrote.